GlassScriptPhysician profile
Alison K Lees
NPI 1295965002
$4,841.03
in general payments reported to CMS, 2019-2025
26 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $681 · 2023: $1,059 · 2024: $1,558 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258 · Education: $496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,257.93 |
| Education | $496.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $822.37 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $499.06 | 2021-2025 | |
| Pfizer INC. | $475.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $440.61 | 2021-2025 | |
| Abbvie INC. | $388.38 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $373.36 | 2022-2025 | Ilumya |
| Lilly USA, LLC | $323.06 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $229.64 | 2021-2025 | Seysara, Klisyri |
| Galderma Laboratories, L.P. | $183.63 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $133.29 | 2022-2024 | Vtama |
| Biofrontera INC. | $132.32 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $126.16 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $104.87 | 2023-2025 | Sotyktu |
| Amgen INC. | $100.38 | 2021-2024 | Otezla |
| Incyte Corporation | $84.99 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $77.35 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021 | |
| Organogenesis INC. | $65.61 | 2024-2025 | Via Matrix |
| Merz North America, INC. | $45.89 | 2022 | |
| Organon LLC | $31.94 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $30.17 | 2024 | |
| Allergan, INC. | $26.34 | 2021 | |
| Kerecis Limited | $22.16 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Verrica Pharmaceuticals INC. | $19.88 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $19.49 | 2025 | Nuzyra |
| Nabriva Therapeutics, Plc | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Lees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.